{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:33:42Z","timestamp":1787009622176,"version":"build-2736575974"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"German Federal Ministry of Education and Research"},{"DOI":"10.13039\/501100002347","name":"BMBF","doi-asserted-by":"publisher","award":["FKZ 01ER0812"],"award-info":[{"award-number":["FKZ 01ER0812"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"BMBF","doi-asserted-by":"publisher","award":["01ER0813"],"award-info":[{"award-number":["01ER0813"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"BMBF","doi-asserted-by":"publisher","award":["01ER0828"],"award-info":[{"award-number":["01ER0828"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>JIA is characterised by a chronic disease course. Once patients achieve a state of inactive disease, there are no established biomarkers to predict the further course of inflammation for these patients. Therefore, the purpose of this study was to quantify serum biomarkers during quiescent disease to evaluate their use in identifying JIA patients at risk for future disease flare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with non-systemic JIA reaching inactive disease status were divided into two groups: 92 patients with future active disease after a median period of 6\u2009months (range 3\u20139) and 80 patients with persistent inactive disease for the following period (median 11\u2009months, range 7\u201316) according to the juvenile arthritis DAS (JADAS). Clinical parameters and serum levels of various biomarkers were measured in the state of inactive disease using immunoassays in both groups and were analysed for their potential to predict the further course of disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Soluble interleukin-2 receptor (sIL-2R) serum levels were significantly higher in patients with future active disease (P\u2009=\u20090.021), which especially applied to patients with RF-negative polyarticular and extended oligoarticular JIA (P\u2009&amp;lt;\u20090.001). Higher sIL-2R serum levels during inactive disease were associated with a greater number of active joints at future active disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients without clinical signs of disease activity already presented with increased sIL-2R serum levels several months before disease relapses, whereas conventional inflammation parameters were not elevated. Determination of sIL-2R serum levels during inactive disease may facilitate identifying patients with subclinical disease activity at risk for future active disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac178","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T08:21:06Z","timestamp":1647937266000},"page":"4975-4984","source":"Crossref","is-referenced-by-count":9,"title":["Soluble interleukin-2 receptor serum levels facilitate prediction of relapses in subgroups of patients with juvenile idiopathic arthritis"],"prefix":"10.1093","volume":"61","author":[{"given":"Linda","family":"Ziegler","sequence":"first","affiliation":[{"name":"Department of Pediatric Rheumatology and Immunology, University Hospital Muenster , Muenster"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Fuehner","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology and Immunology, University Hospital Muenster , Muenster"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kessel","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology and Immunology, University Hospital Muenster , Muenster"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9247-4729","authenticated-orcid":false,"given":"Claas","family":"Hinze","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology and Immunology, University Hospital Muenster , Muenster"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Klotsche","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, German Rheumatism Research Center , Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Niewerth","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, German Rheumatism Research Center , Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Minden","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, German Rheumatism Research Center , Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Foell","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology and Immunology, University Hospital Muenster , Muenster"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"2022112912441065300_keac178-B1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"2022112912441065300_keac178-B2","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2022112912441065300_keac178-B3","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.autrev.2011.02.001","article-title":"The pathogenesis of oligoarticular\/polyarticular vs systemic juvenile idiopathic arthritis","volume":"10","author":"Lin","year":"2011","journal-title":"Autoimmun Rev"},{"key":"2022112912441065300_keac178-B4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2014.212","article-title":"Management of juvenile idiopathic arthritis: hitting the target","volume":"11","author":"Hinze","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2022112912441065300_keac178-B5","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1136\/annrheumdis-2014-205372","article-title":"The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort","volume":"74","author":"Guzman","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022112912441065300_keac178-B6","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2022112912441065300_keac178-B7","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/art.24516","article-title":"Development and validation of a composite disease activity score for juvenile idiopathic arthritis","volume":"61","author":"Consolaro","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2022112912441065300_keac178-B8","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/acr.20497","article-title":"American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis","volume":"63","author":"Wallace","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2022112912441065300_keac178-B9","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/art.24823","article-title":"Comparison of clinical versus ultrasound-determined synovitis in juvenile idiopathic arthritis","volume":"61","author":"Magni-Manzoni","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2022112912441065300_keac178-B10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/annrheumdis-2011-201049","article-title":"MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis","volume":"72","author":"Malattia","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022112912441065300_keac178-B11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12969-021-00553-x","article-title":"Trajectories of disease courses in the inception cohort of newly diagnosed patients with JIA (ICON-JIA): the potential of serum biomarkers at baseline","volume":"19","author":"Ganeva","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"2022112912441065300_keac178-B12","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1136\/annrheumdis-2011-200237","article-title":"Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting","volume":"71","author":"Nordal","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022112912441065300_keac178-B13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrrheum.2013.14","article-title":"Mechanistic biomarkers for clinical decision making in rheumatic diseases","volume":"9","author":"Robinson","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"2022112912441065300_keac178-B14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/ard.2006.061853","article-title":"Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study","volume":"66","author":"de Jager","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2022112912441065300_keac178-B15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/art.1780380209","article-title":"Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes","volume":"38","author":"Mangge","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2022112912441065300_keac178-B16","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2010.375","article-title":"Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial","volume":"303","author":"Foell","year":"2010","journal-title":"JAMA"},{"key":"2022112912441065300_keac178-B17","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1136\/annrheumdis-2012-201329","article-title":"Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study","volume":"71","author":"Gerss","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022112912441065300_keac178-B18","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/phar.1938","article-title":"Cytokine biomarkers of disease activity and therapeutic response after initiating methotrexate therapy in patients with Juvenile Idiopathic Arthritis","volume":"37","author":"Funk","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2022112912441065300_keac178-B19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/cei.12782","article-title":"The impact of disease activity and tumour necrosis factor-alpha inhibitor therapy on cytokine levels in juvenile idiopathic arthritis","volume":"184","author":"Walters","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"2022112912441065300_keac178-B20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.clim.2012.11.008","article-title":"Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers","volume":"147","author":"Kessel","year":"2013","journal-title":"Clin Immunol"},{"key":"2022112912441065300_keac178-B21","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1164\/rccm.201209-1602OC","article-title":"Proinflammatory S100A12 can activate human monocytes via toll-like receptor 4","volume":"187","author":"Foell","year":"2013","journal-title":"Am J Resp Crit Care"},{"key":"2022112912441065300_keac178-B22","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.jaci.2018.06.027","article-title":"Calcium and zinc tune autoinflammatory Toll-like receptor 4 signaling by S100A12","volume":"142","author":"Kessel","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2022112912441065300_keac178-B23","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1172\/JCI89867","article-title":"Autoinhibitory regulation of S100A8\/S100A9 alarmin activity locally restricts sterile inflammation","volume":"128","author":"Vogl","year":"2018","journal-title":"J Clin Invest"},{"key":"2022112912441065300_keac178-B24","doi-asserted-by":"crossref","first-page":"e000074","DOI":"10.1136\/rmdopen-2015-000074","article-title":"The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort","volume":"1","author":"Sengler","year":"2015","journal-title":"RMD Open"},{"key":"2022112912441065300_keac178-B25","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1136\/annrheumdis-2012-202031","article-title":"Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis","volume":"72","author":"McErlane","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022112912441065300_keac178-B26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12969-016-0085-5","article-title":"Clinical outcome measures in juvenile idiopathic arthritis","volume":"14","author":"Consolaro","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"2022112912441065300_keac178-B27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"2022112912441065300_keac178-B28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/0003-4819-113-8-619","article-title":"The soluble interleukin-2 receptor: biology, function, and clinical application","volume":"113","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"2022112912441065300_keac178-B29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1155\/MI.2005.121","article-title":"On the role of sIL-2R measurements in rheumatoid arthritis and cancers","volume":"2005","author":"Witkowska","year":"2005","journal-title":"Mediators Inflamm"},{"key":"2022112912441065300_keac178-B30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"2022112912441065300_keac178-B31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/asheducation-2005.1.82","article-title":"Familial and acquired hemophagocytic lymphohistiocytosis","volume":"2005","author":"Janka","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2022112912441065300_keac178-B32","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/bloodadvances.2017012310","article-title":"Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH","volume":"1","author":"Hayden","year":"2017","journal-title":"Blood Adv"},{"key":"2022112912441065300_keac178-B33","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/art.22416","article-title":"The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis","volume":"56","author":"Bleesing","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2022112912441065300_keac178-B34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0896-8411(88)90005-4","article-title":"Serum interleukin-2-receptor in rheumatoid arthritis: a prognostic indicator of disease activity?","volume":"1","author":"Wood","year":"1988","journal-title":"J Autoimmun"},{"key":"2022112912441065300_keac178-B35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2249.1990.tb05398.x","article-title":"Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus","volume":"82","author":"ter Borg","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"2022112912441065300_keac178-B36","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1007\/BF02212697","article-title":"Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse","volume":"40","author":"Louis","year":"1995","journal-title":"Dig Dis Sci"},{"key":"2022112912441065300_keac178-B37","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1038\/s41598-021-86251-w","article-title":"Serum biomarkers confirming stable remission in inflammatory bowel disease","volume":"11","author":"Kessel","year":"2021","journal-title":"Sci Rep"},{"key":"2022112912441065300_keac178-B38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1546-0096-6-8","article-title":"Elevated serum levels of soluble CD154 in children with juvenile idiopathic arthritis","volume":"6","author":"Prahalad","year":"2008","journal-title":"Pediatr Rheumatol Online J"},{"key":"2022112912441065300_keac178-B39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00296-002-0191-1","article-title":"Circulating interleukin-6, soluble interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-10 levels in juvenile chronic arthritis: correlations with soft tissue vascularity assessed by power Doppler sonography","volume":"22","author":"Shahin","year":"2002","journal-title":"Rheumatol Int"},{"key":"2022112912441065300_keac178-B40","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/ng.2614","article-title":"Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis","volume":"45","author":"Hinks","year":"2013","journal-title":"Nat Genet"},{"key":"2022112912441065300_keac178-B41","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/annrheumdis-2016-210025","article-title":"Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases","volume":"76","author":"Hinks","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022112912441065300_keac178-B42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-015-0723-1","article-title":"MRP8\/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis","volume":"17","author":"Anink","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2022112912441065300_keac178-B43","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/art.40727","article-title":"Serum S100A8\/A9 and S100A12 levels in children with polyarticular forms of juvenile idiopathic arthritis: relationship to maintenance of clinically inactive disease during anti-tumor necrosis factor therapy and occurrence of disease flare after discontinuation of therapy","volume":"71","author":"Hinze","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022112912441065300_keac178-B44","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1093\/rheumatology\/kez590","article-title":"MRP8\/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis","volume":"59","author":"Barendregt","year":"2020","journal-title":"Rheumatology"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac178\/43349626\/keac178.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/12\/4975\/47386061\/keac178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/12\/4975\/47386061\/keac178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T07:47:20Z","timestamp":1669708040000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/12\/4975\/6552997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,3,23]]},"published-print":{"date-parts":[[2022,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac178","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,3,23]]}}}